invIOs INNOVATIVE IMMUNO-ONCOLOGY Secures $8.93M in Series A Funding Round to Revolutionize Cancer Therapeutics!

invIOs INNOVATIVE IMMUNO-ONCOLOGY, a pioneering private biotech company established as a spin-out from APEIRON Biologics, has successfully raised an impressive $8.93 million in its latest funding round. Founded in 2022, invIOs is dedicated to the discovery and development of novel cancer therapeutics that aim to empower and educate the immune system in its battle against cancer. With a focused pipeline that targets solid tumors, the company is strategically positioned at the forefront of earlier-stage development, specializing in transitioning innovative assets from discovery and pre-clinical stages into clinical trials. The newly acquired funds will enhance invIOs' capabilities, enabling accelerated research and the advancement of their promising therapeutics. The company’s highly motivated team of 35 experts boasts deep knowledge across the biotechnology value chain, including research and development, clinical development, CMC (Chemistry, Manufacturing, and Controls), intellectual property, and other crucial domains. This infusion of capital underscores the confidence of investors in invIOs' vision and its commitment to bringing ground-breaking cancer treatments to the forefront of medicine. As the team continues its efforts to deliver individualized and targeted approaches against cancer, their overarching goal remains clear: to transform patients' lives and to ensure that cancer doesn’t define their future. The funding will play a pivotal role in furthering these initiatives, reinforcing invIOs’ dedication to making significant strides in the fight against this devastating disease.